Project Grant R21CA283138
Award Date
7/15/24
Completion Date
6/30/26
Dollars Obligated
$399K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Richmond, VA 23219, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $415,257 to the University of Virginia to conduct research aimed at identifying epigenetic and transcriptomic drivers of racial disparities in colorectal cancer risk and site-specific tumor development. The key products and services to be delivered under this 2-year award include: Identifying site-specific DNA methylation-associated gene expression signatures across different...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), will support the University of South Carolina's investigation of novel targeted therapies, effects of comorbidities, and multi-level contributors to racial, socioeconomic, and rural disparities in lung and colon cancer survival trajectories. With $334,233 in funding over the project period of September 2024 to August 2029, the research will leverage...
This $2,035,551 federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program supports the development and external validation of new personalized colorectal cancer (CRC) risk prediction models tailored for Black American men and women. The award recipient, Trustees of Boston University, will leverage longitudinal data from large prospective cohorts of Black adults to build dynamic risk models using advanced...
This Project Grant award from the Department of Health and Human Services National Institutes of Health National Cancer Institute provides $582,100 to East Carolina University to support research on the role of mitochondrial complex I deficiency in colorectal cancer (CRC) tumor growth and progression. The research aims to elucidate how accumulated mitochondrial DNA mutations that disrupt complex I activity can paradoxically support CRC tumorigenesis, despite the general requirement for...
The National Cancer Institute (NCI) awarded a $368,288 federal Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. The grant supports a 5-year research project investigating the molecular mechanisms contributing to disparate outcomes experienced by lung cancer patients of African ancestry. The study aims to: 1) determine how EGFR signaling differs based on patient genetic...
This Project Grant award, with ID R21CA294050, is funded by the National Cancer Institute (NCI) under the federal Cancer Cause and Prevention Research program (CFDA 93.393). The $405,316 grant will support research to investigate the role of the inflammatory dietary pattern in the gut and colon tissue microbiomes, and the impact on survival outcomes among colorectal cancer patients. The research will leverage data from the ColoCare study cohort and the Oncology Information Exchange Network to...
The National Cancer Institute has awarded a $730,398 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the Sloan-Kettering Institute for Cancer Research in New York to conduct a 5-year research project titled "Understanding Lung Cancer Genomics in Patients of African Ancestry". The project aims to: Identify and validate genomic differences between lung cancer patients of African and European ancestry, with a focus on drug-targetable and clinically relevant biomarkers. This...
The $181,640 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the principal investigator's efforts to improve survival of patients with gastrointestinal malignancies, particularly colorectal and anal cancer. The award funds the evaluation of circulating tumor DNA (ctDNA) and extravesicle RNA (evRNA) as predictive biomarkers for response to immunotherapy combinations in NCI-sponsored clinical trials. Specifically, the PI will analyze...
This $720,252 Cooperative Agreement award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program will support a research project led by the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts. The project aims to identify genetic variants that confer risk of common cancers, particularly prostate cancer, across diverse ancestral populations. The key products and services to be delivered include: Profiling regulatory element...
The National Cancer Institute (NCI) awarded a $560,297 Project Grant under the Cancer Biology Research (CFDA 93.396) program to the Icahn School of Medicine at Mount Sinai. The grant, with a project period from September 1, 2024 to August 31, 2029, will fund research to functionally characterize oncofetal stem cells (ONFSCs) in colorectal cancer (CRC). The research aims to determine the molecular drivers of the ONFSCS and their role in CRC progression and treatment resistance, as well as...